DAVID A contact WOHL

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study
    David A Wohl
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Antimicrob Agents Chemother 57:784-8. 2013
  2. doi request reprint Management of morphologic changes associated with antiretroviral use in HIV-infected patients
    David Alain Wohl
    AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 49:S93-S100. 2008
  3. doi request reprint Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy
    David A Wohl
    University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Infect Dis 47:1105-8. 2008
  4. ncbi request reprint Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy
    D A Wohl
    Div of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Infect Dis 43:645-53. 2006
  5. ncbi request reprint Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia
    David A Wohl
    Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Infect Dis 41:1498-504. 2005
  6. ncbi request reprint The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy
    D A Wohl
    University of North Carolina, Chapel Hill, North Carolina 27516 7215, USA
    HIV Clin Trials 6:136-46. 2005
  7. ncbi request reprint Body shape, lipid, and cardiovascular complications of HIV therapy
    David Alain Wohl
    AIDS Research and Treatment Unit, University of North Carolina, Chapel Hill, NC 27599, USA
    Curr HIV/AIDS Rep 2:74-82. 2005
  8. pmc Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030
    D A Wohl
    University of North Carolina, Chapel Hill, North Carolina, USA
    HIV Clin Trials 10:143-52. 2009
  9. ncbi request reprint Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies
    David A Wohl
    Division of Infectious Diseases, The University of North Carolina, Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 38:538-44. 2005
  10. ncbi request reprint Considering metabolic issues when initiating HIV therapy
    David Alain Wohl
    The University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    Curr HIV/AIDS Rep 4:119-25. 2007

Research Grants

Detail Information

Publications35

  1. pmc Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study
    David A Wohl
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Antimicrob Agents Chemother 57:784-8. 2013
    ..Based on plasma PK, and with similar adherence rates, the performance of RAL among HIV-infected African-Americans should be no different than that of infected patients who are white...
  2. doi request reprint Management of morphologic changes associated with antiretroviral use in HIV-infected patients
    David Alain Wohl
    AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 49:S93-S100. 2008
    ..The potential increase in risk of cardiovascular disease associated with these metabolic disturbances is also discussed...
  3. doi request reprint Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy
    David A Wohl
    University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Infect Dis 47:1105-8. 2008
    ..5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin...
  4. ncbi request reprint Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy
    D A Wohl
    Div of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Infect Dis 43:645-53. 2006
    ..On the basis of a review of the medical literature published and/or data presented before April 2006, we have prepared a guide to assist the clinician in the detection and management of these complications...
  5. ncbi request reprint Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia
    David A Wohl
    Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Infect Dis 41:1498-504. 2005
    ..Whether omega-3 fatty acid supplementation can reduce hypertriglyceridemia associated with antiretroviral therapy is not known...
  6. ncbi request reprint The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy
    D A Wohl
    University of North Carolina, Chapel Hill, North Carolina 27516 7215, USA
    HIV Clin Trials 6:136-46. 2005
    ....
  7. ncbi request reprint Body shape, lipid, and cardiovascular complications of HIV therapy
    David Alain Wohl
    AIDS Research and Treatment Unit, University of North Carolina, Chapel Hill, NC 27599, USA
    Curr HIV/AIDS Rep 2:74-82. 2005
    ..Development of antiretrovirals with fewer metabolic adverse effects will reduce the incidence of these and similar disorders during HIV therapy...
  8. pmc Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030
    D A Wohl
    University of North Carolina, Chapel Hill, North Carolina, USA
    HIV Clin Trials 10:143-52. 2009
    ....
  9. ncbi request reprint Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies
    David A Wohl
    Division of Infectious Diseases, The University of North Carolina, Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 38:538-44. 2005
    ..To determine the association of cytomegalovirus (CMV) viremia with CMV disease and death in patients with AIDS...
  10. ncbi request reprint Considering metabolic issues when initiating HIV therapy
    David Alain Wohl
    The University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    Curr HIV/AIDS Rep 4:119-25. 2007
    ....
  11. doi request reprint Deconstructing most recent antiretroviral recommendations
    David Alain Wohl
    AIDS Clinical Trials Unit Chapel Hill, Division of Infectious Diseases, The University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    Curr HIV/AIDS Rep 7:77-84. 2010
    ..Understanding the recommendations of the major US treatment guideline for initial HIV therapy is essential for clinicians caring for such patients...
  12. pmc Locating the places people meet new sexual partners in a southern US city to inform HIV/STI prevention and testing efforts
    David A Wohl
    The Center for AIDS Research, The University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    AIDS Behav 15:283-91. 2011
    ..The systematic methodology used was successful in locating venues where risky encounters are established and reveal opportunities for targeted HIV prevention and testing programs as well as research...
  13. pmc Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trial
    David A Wohl
    The University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    AIDS Behav 15:356-64. 2011
    ....
  14. ncbi request reprint Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267
    David A Wohl
    Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    J Infect Dis 185:1359-63. 2002
    ..Previous suggestions of autoinduction of drug metabolism were not confirmed by this study. At the doses studied, thalidomide was tolerated well and had linear pharmacokinetics...
  15. ncbi request reprint Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity
    David A Wohl
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    J Acquir Immune Defic Syndr 35:274-8. 2004
    ..This variability may reflect differences in the definition of and risk factors for hyperlactatemia and/or techniques for venous lactate collection...
  16. ncbi request reprint Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates
    David A Wohl
    Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, 27599, USA
    Clin Infect Dis 36:1572-6. 2003
    ..Different methods used to measure adherence revealed significantly different levels of adherence. These findings suggest that use of DOT does not ensure adherence to antiretroviral therapy...
  17. pmc Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison system
    David L Rosen
    University of North Carolina, Chapel Hill, 27599 7435, USA
    Am J Public Health 99:1123-30. 2009
    ..We identified factors associated with testing HIV positive in a prison system performing voluntary HIV testing on inmates and estimated the number of undetected HIV cases to evaluate the efficacy of risk-factor-based HIV testing...
  18. pmc Timing and duration of incarceration and high-risk sexual partnerships among African Americans in North Carolina
    Maria R Khan
    Department of Epidemiology, University of North Carolina at Chapel Hill, NC, USA
    Ann Epidemiol 18:403-10. 2008
    ..Incarceration may contribute to HIV transmission by disrupting stable partnerships and promoting high-risk partnerships. We investigated incarceration and high-risk partnerships among African Americans in North Carolina...
  19. pmc All-cause and cause-specific mortality among men released from state prison, 1980-2005
    David L Rosen
    University of North Carolina Schools of Medicine and Public Health, Chapel Hill, NC, USA
    Am J Public Health 98:2278-84. 2008
    ..We compared mortality of ex-prisoners and other state residents to identify unmet health care needs among former prisoners...
  20. doi request reprint Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
    Charles B Hicks
    Department of Medicine, Duke University, Durham, North Carolina 27710, USA
    AIDS Res Hum Retroviruses 25:395-403. 2009
    ..48 mg/dl). In conclusion, through 96 weeks, FPV/r100 was more effective and prompted less elevation in triglycerides than FPV/r200...
  21. pmc An evaluation of HIV testing among inmates in the North Carolina prison system
    David L Rosen
    Schools of Public Health and Medicine, University of North Carolina, Chapel, Chapel Hill, NC, 27599 7435, USA
    Am J Public Health 99:S452-9. 2009
    ..We examined the use of voluntary HIV testing among state prisoners in the North Carolina prison system...
  22. pmc Incarceration and risky sexual partnerships in a southern US city
    Maria R Khan
    Department of Epidemiology, School of Public Health, University of North Carolina, CB 7435, Chapel Hill, NC 27514, USA
    J Urban Health 85:100-13. 2008
    ..Correctional-facility and community-based HIV prevention, with substance abuse treatment, should reach currently and formerly incarcerated individuals and their sexual partners...
  23. ncbi request reprint Sexual behaviours of HIV-seropositive men and women following release from prison
    Becky L Stephenson
    Schools of Medicine, Public Health, Nursing, and Dentistry at the University of North Carolina, Chapel Hill, NC 27599, USA
    Int J STD AIDS 17:103-8. 2006
    ..These results suggest that regular partners of HIV-infected prison releasees are at risk of acquiring HIV infection, and secondary risk-reduction strategies are needed for HIV-infected prison releasees...
  24. pmc Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals
    Becky L Stephenson
    Division of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Public Health Rep 120:84-8. 2005
    ..The purpose of this study was to determine the effect of release from prison and subsequent re-incarceration on the viral loads of HIV-infected individuals receiving highly active antiretroviral therapy (HAART)...
  25. ncbi request reprint Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy
    C Scott Hultman
    Division of Plastic and Reconstructive Surgery, University of North Carolina, Chapel Hill, North Carolina 27599 7195, USA
    Ann Plast Surg 58:255-63. 2007
    ..Medical treatment of fat redistribution is usually ineffective. We evaluated the efficacy and safety of the surgical management of HIV lipodystrophy...
  26. ncbi request reprint Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients
    Sonia Napravnik
    Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    AIDS 21:825-34. 2007
    ..HIV-1 triple-class antiretroviral drug resistance (TC-DR) may substantially limit therapeutic options and compromise clinical outcomes...
  27. ncbi request reprint A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy
    Becky L White
    Department of Medicine, Center for Infectious Diseases, University of North Carolina Schools of Medicine and Public Health, Chapel Hill, North Carolina, USA
    AIDS Patient Care STDS 20:408-17. 2006
    ..72; p < 0.001). This study provides preliminary support for the psychometric properties of the survey in this correctional setting...
  28. ncbi request reprint Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies
    David A Wohl
    University of North Carolina, Chapell Hill, NC, USA
    Top HIV Med 12:89-93. 2004
    ..This article summarizes a presentation by David A. Wohl, MD, at the February 2004 International AIDS Society-USA course in Atlanta...
  29. ncbi request reprint Predictors of repeat testing and HIV seroconversion in a sexually transmitted disease clinic population
    Lisa B Hightow
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Sex Transm Dis 31:455-9. 2004
    ..This study assessed the extent of and characteristics associated with repeat HIV testing in persons presenting to a sexually transmitted disease (STD) clinic...
  30. ncbi request reprint Availability of and access to medical services among HIV-infected inmates incarcerated in North Carolina county jails
    David L Rosen
    Department of Epidemiology, University of North Carolina at Chapel Hill, USA
    J Health Care Poor Underserved 15:413-25. 2004
    ..quot; Overall, our data indicate that few North Carolina jail inmates are tested for HIV. Greater protection of confidentiality may improve screening and treatment of HIV-infected inmates...
  31. ncbi request reprint HIV and incarceration: dual epidemics
    David A Wohl
    AIDS Clinical Research and Treatment Unit, University of North Carolina at Chapel Hill, USA
    AIDS Read 16:247-50, 257-60. 2006
    ..Interventions to enhance identification of infected inmates, prevention counseling, and treatment of inmates with HIV/AIDS are required to stem the contribution of incarceration to the spread of HIV infection...
  32. ncbi request reprint Editorial comment: fish oil to keep the cardiologist away?
    David Alain Wohl
    AIDS Read 17:371. 2007
  33. ncbi request reprint Editorial comment: correcting facial lipoatrophy has little to do with vanity
    David Alain Wohl
    AIDS Read 15:372. 2005
  34. ncbi request reprint HIV treatment series. Metabolic complications myths. Some misunderstandings about treatment
    David Alain Wohl
    Posit Aware 18:25-8. 2007
  35. ncbi request reprint Diagnosing primary HIV infection
    Christopher D Pilcher
    Ann Intern Med 136:488-9; author reply 488-9. 2002

Research Grants10

  1. Incarceration and HIV-Infected Inmates
    David A Wohl; Fiscal Year: 2010
    ..Aim 2. Determine the inmate, nurse-counselor and facility characteristics associated with agreeing to HIV VCT. Aim 3. Explore the risks associated with receiving an HIV diagnosis in prison. ..
  2. Incarceration and HIV-Infected Inmates
    David Wohl; Fiscal Year: 2007
    ..Aim 2. Determine the inmate, nurse-counselor and facility characteristics associated with agreeing to HIV VCT. Aim 3. Explore the risks associated with receiving an HIV diagnosis in prison. ..
  3. HIV+ Prison Releases to Access to HIV Care and Services
    David Wohl; Fiscal Year: 2007
    ..2. BCM will reduce intimate and drug related HIV transmission risk behaviors during the year following prison release. ..
  4. RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners
    DAVID A contact WOHL; Fiscal Year: 2010
    ....